Tag: genetech

Roche's Gazyva growth plans endengered after Lymphoma trial failure Feature

Roche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up. The newer med failed to best gold-standard Rituxan in previously untreated patients with diffuse large B-cell lymphoma, according to topline results from a new trial.

Read More
Trymore Magomana | magomana.com | (c) 2008 - 2016
Trymore Magomana